Close Menu

product launch

Visium, which provides gene expression information along with spatial information from the same tissue sample, will be shipped later next month.

The company's goal is to serve what it sees as a massive but underaddressed target group: Asian women.

At Belgium's VIB, researchers have designed custom panels with CNV detection in mind to get better data on single-cell genomic changes during cancer treatment.

The San Diego-based firm has developed a new extracellular RNA sequencing method that it believes could be used for cancer diagnostics.

The company believes that Xdrop will find adopters in academia and clinical research, although diagnostics is on its radar.

The German company's new Genome Enhancer product is an adaptation of its flagship multi-omics software for clinicians and biologists without bioinformatics expertise.

Illumina plans to upgrade all its NIPT customers to version 2 of its VeriSeq solution over the next year.

The firm said it is helping customers convert from SNP genotyping arrays to an NGS workflow, which may allow it to access the ag-bio and direct-to-consumer markets.

The company is hoping to add outreach to make sure individuals who want counseling get it, and to better understand the reasons why others might not.

A collaboration with ATAC-seq experts at the Broad Institute suggests the Bio-Rad assay can analyze tens of thousands of cells per experiment.

Pages

Following discrimination allegations, NICHD's Constantine Stratakis withdraws from a new position at the Research Institute of the McGill University Health Center, Science reports.

US President Donald Trump has threatened to cut World Health Organization funding over its pandemic response, which would affect its ability to do its work and which he might not be able to do.

The US Securities and Exchange Commission has halted the sales of a handful of stocks over claims made about the coronavirus.

In Nature this week: comparative analyses of single-cell RNA sequencing protocols uncover differences between approaches, and more.